Influence of Exercise Training on Expression of Some Cerebral Proteins Involved in APP Processing in Rat Models of Alzheimer's Disease: A Meta-Analysis

Document Type : Research Paper

Authors

1 MSc in Exercise Physiology, Department of Sport Sciences, Faculty of Education and Psychology, Azarbaian Sahid Madani University, Tabriz, Iran

2 Associate Professor, Department of Sport Sciences, Faculty of Education and Psychology, Azarbaian Sahid Madani University, Tabriz, Iran

3 Associate Professor, Department of Exercise Physiology, Faculty of physical education and Sport Sciences, University Tabriz, Tabriz, Iran

Abstract
Background and Purpose
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. The amyloid-β (Aβ) peptide, derived from the cleavage of amyloid precursor protein (APP), is a key therapeutic target in AD. APP is processed via two pathways: the non-amyloidogenic pathway, mediated by α-secretase (ADAM10), and the amyloidogenic pathway, mediated by β-secretase (BACE1). The balance between these pathways determines Aβ production, with dysregulation contributing to AD pathogenesis.
Exercise on the other hand has been shown to modulate APP processing, shifting it toward the non-amyloidogenic pathway to reduce Aβ production. However, the underlying mechanisms is poorly understood. This study aimed to systematically review and meta-analyze the effects of exercise training on cerebral ADAM10, BACE1, sAPPα, sAPPβ, and Aβ expression, as well as spatial memory function in rat models of AD.
 
Materials and Methods
This systematic review and meta-analysis followed PRISMA guidelines. Animal studies with control groups investigating the effects of at least 3 weeks of exercise training in rat models of AD, published in peer-reviewed journals up to July 2024, were retrieved from PubMed, Google Scholar, SID, and Magiran databases. Studies combining exercise with other interventions, Duplicate publications and review articles were excluded from analysis. Two reviewers independently screened titles and abstracts for eligibility. Disagreements were resolved through consultation with a third reviewer.
Random-effects model was used to calculate standardized mean differences (SMD) and 95% confidence intervals (CIs). Heterogeneity was assessed using the I² statistic, with values >50% indicating high heterogeneity. Publication bias was evaluated using Egger’s regression test. Meta-regression and subgroup analyses were performed to explore the effects of moderators.
 Findings
A total of 14 interventions were included in the meta-analysis. Primary Outcome measure was Cerebral ADAM10 Expression. High heterogeneity (I² > 50%) was observed for all outcomes.
Egger’s regression indicated no significant publication bias. The net effect of exercise training on ADAM10 expression was not statistically significant (SMD = 0.73, 95% CI: -0.43 to 1.91). moreover, subgroup analysis revealed a significant increase in hippocampal ADAM10 expression (SMD = 2.48, p = 0.001).
Secondary Outcomes are listed below:
Cerebral BACE1 Expression: No significant overall effect was observed. Subgroup analysis showed a significant decrease in hippocampal BACE1 expression (SMD = -2.03, p = 0.001).
sAPPα and sAPPβ Expression: Exercise training significantly reduced sAPPβ expression (SMD = -2.59, 95% CI: -3.80 to -1.39). No significant effect was observed for sAPPα.
Aβ Expression: Exercise training significantly reduced Aβ expression (SMD = -4.03, 95% CI: -5.13 to -2.92).
Spatial Memory Function: Exercise training improved spatial memory function, though heterogeneity was high.
 Conclusion
The findings suggest that exercise training modulates APP processing in rat models of AD, favoring an elevated hippocampal non-amyloidogenic pathway, based on a significant increase in ADAM10 expression in this region.
On the other hand, a dimineshed hippocampal BACE1 expression could be indicate on a suppressed amyloidogenic pathway which is thought to can reduced cerebral Aβ burden. Other finding of this study was related to a significant decrease in Aβ expression which is in line with our previous findings to reduce amyloid burden.
The exact mechanisms of exercise training in reduction of cerebral Aβ burden was attributed to induce a shif in APP processing toward the non-amyloidogenic pathway through upregulation of ADAM10 and downregulation of BACE1. Morereover, exercise-induced increases in brain-derived neurotrophic factor (BDNF) may further modulate APP processing and reduce Aβ production. However, this study has some limmitations e.g high heterogeneity across studies that limits the generalizability of the findings. Furthuremore, most of included studies used rodent models, which their results can not be fully generalizable to human patients. Additionally, variability in exercise protocols and outcome measures may contribute to inconsistent results.
Anyway, exercise training shows promise as a non-pharmacological intervention for reducing amyloid burden in AD, however, more clinical trials remain to be provided in human subjects. The observed increases in ADAM10 and converse decreases in BACE1 and Aβ expression, particularly in the hippocampus, suggest that exercise may mitigate amyloid pathology in early AD stages.
For future research it is suggested to conduct longitudinal studies to assess the long-term effects of exercise on APP processing and Aβ levels. Moreover, investigating the straight role of exercise-induced BDNF in modulating APP processing could be instumental. Additionally, it seems exact exploration the effects of different exercise modalities (e.g., aerobic, resistance) on AD biomarkers should be conducted in the future studies in thia area.
Article Message
Increased expression of ADAM10 and decreased expression of BACE1 in the hippocampus, along with reduced sAPPβ and Aβ levels in mixed brain tissue samples of AD modes due to exercise training, herald a potential reduction in cerebral amyloid burden, especially in the early stages of AD; however, these findings still need to be confirmed in human patients.
 Acknowledgments
Thanks, and appreciation are extended to all individuals or groups who collaborated in conducting this research.
 Conflict of interest
The authors declare no competing interests regarding the publication of this article.
 

Keywords

Main Subjects


  1. Liu-Seifert H, Siemers E, Sundell K, Price K, Han B, Selzler K, et al. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. Journal of Alzheimer's Disease. 2015;43(3):949-55.
  2. Zahodne LB, Manly JJ, MacKay-Brandt A, Stern Y. Cognitive declines precede and predict functional declines in aging and Alzheimer’s disease. PloS one. 2013;8(9): e73645.
  3. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362(4):329-44.
  4. Parbo P, Ismail R, Sommerauer M, Stokholm MG, Hansen AK, Hansen KV, et al. Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study. 2018; 117:211-6.
  5. Khan SS, Bloom GS. Tau: the center of a signaling nexus in Alzheimer's disease. Frontiers in Neuroscience. 2016; 10:31.
  6. Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harbor Perspectives in Medicine. 2012;2(5): a006270.
  7. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. Journal of Biological Chemistry. 2008;283(44):29615-9.
  8. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-6.
  9. Endres K, Deller T. Regulation of alpha-secretase ADAM10 in vitro and in vivo: genetic, epigenetic, and protein-based mechanisms. Frontiers in Molecular Neuroscience. 2017; 10:56.
  10. Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, et al. A novel pathway for amyloid precursor protein processing. Neurobiology of Aging. 2011;32(6):1090-8.
  11. Elsworthy RJ, Dunleavy C, Whitham M, Aldred S. Exercise for the prevention of Alzheimer's disease: multiple pathways to promote non-amyloidogenic AβPP processing. Aging and Health Research. 2022:100093.
  12. Goldstein MR, Cheslock M. On the prevention and treatment of Alzheimer’s disease: Control the promoters and look beyond the brain. Medical Hypotheses. 2021; 154:110645.
  13. Zhao W, Liu Y, Xu L, He Y, Cai Z, Yu J, et al. Targeting necroptosis as a promising therapy for Alzheimer’s disease. ACS Chem Neurosci. 2022:13(12):1697-713
  14. Khezri MR, Mohebalizadeh M, Ghasemnejad-Berenji M. Therapeutic potential of ADAM10 modulation in Alzheimer’s disease: a review of the current evidence. Cell Communication and Signaling. 2023;21(1):60.
  15. Marko DM, MacPherson REJAJoP-R, Integrative, Physiology C. APP processing: a biochemical competition influenced by exercise-induced signaling mediators? Am J Physiol Regul Integr Comp Physiol. 2022;323(2):R169-R80.
  16. Tan Z-X, Dong F, Wu L-Y, Feng Y-S, Zhang F. The beneficial role of exercise on treating Alzheimer’s disease by inhibiting β-Amyloid peptide. Molecular Neurobiology. 2021;58(11):5890-906.
  17. Elsworthy RJ, Dunleavy C, Whitham M, Aldred S. Exercise for the prevention of Alzheimer's disease: multiple pathways to promote non-amyloidogenic AβPP processing. Aging and Health Research. 2022;2(3):100093.
  18. Xu L, Liu R, Qin Y, Wang TJTN. Brain metabolism in Alzheimer’s disease: biological mechanisms of exercise. Transl Neurodegener. 2023;12(1):33.
  19. Baranowski BJ, Mohammad A, Finch MS, Brown A, Dhaliwal R, Marko DM, et al. Exercise training and BDNF injections alter amyloid precursor protein (APP) processing enzymes and improve cognition. J Appl Physiol (1985). 2023;135(1):121-35.
  20. Ebrahimi K, Majdi A, Baghaiee B, Hosseini SH, Sadigh-Eteghad S. Physical activity and beta-amyloid pathology in Alzheimer's disease: A sound mind in a sound body. EXCLI Journal. 2017; 16:959-72.
  21. Marko D. APP processing: a biochemical competition influenced by exercise-induced signalling mediators. Am J Physiol Regul Integr Comp Physiol. 323(2): R169-R180.
  22. Zhang X-L, Zhao N, Xu B, Chen X-H, Li T-JJN. Treadmill exercise inhibits amyloid-β generation in the hippocampus of APP/PS1 transgenic mice by reducing cholesterol-mediated lipid raft formation. Neuroreport. 2019;30(7):498-503.
  23. Jaberi S, Fahnestock M. Mechanisms of the beneficial effects of exercise on brain-derived neurotrophic factor expression in Alzheimer’s disease. Biomolecules. 2023;13(11):1577.
  24. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-16.
  25. Vardarajan BN, Faber KM, Bird TD, Bennett DA, Rosenberg R, Boeve BF, et al. Age-specific incidence rates for dementia and Alzheimer disease in NIA-LOAD/NCRAD and EFIGA families: National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA). JAMA neurology. 2014;71(3):315-23.
  26. Davidson TL, Stevenson RJ. Vulnerability of the hippocampus to insults: links to blood–brain barrier dysfunction. Int J Mol Sci. 2024;25(4):1991.
  27. Ma L-L, Wang Y-Y, Yang Z-H, Huang D, Weng H, Zeng X-T. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Military Medical Research. 2020;7(1):7.
  28. Andrade C. Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets. J Clin Psychiatry. 2020;81(5):11349.
  29. Wang X, Wang C, Pei G. α-secretase ADAM10 physically interacts with β-secretase BACE1 in neurons and regulates CHL1 proteolysis. J Mol Cell Biol. 2018;10(5):411-22.
  30. Oliveira Monteiro e Pereira de Almeida MP, Valle Pedroso R, Mantellatto Grigoli M, Vicente Silva T, Manzine PR, Cominetti MR. ADAM10 as a biomarker for Alzheimer's disease: A systematic review. Revue Neurologique. 2024;180(1):1-11.
  31. Wetzel S, Seipold L, Saftig P. The metalloproteinase ADAM10: A useful therapeutic target? Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2017;1864(11, Part B):2071-81.
  32. Khezri MR, Mohebalizadeh M, Ghasemnejad-Berenji M. Therapeutic potential of ADAM10 modulation in Alzheimer's disease: a review of the current evidence. Cell Commun Signal. 2023;21(1):60.
  33. Hönekopp J, Linden AH. Heterogeneity estimates in a biased world. PLoS One. 2022;17(2):e0262809.
  34. Zarini-Gakiye E, Vaezi G, Parivar K, Sanadgol N. Age and dose-dependent effects of alpha-lipoic acid on human microtubule- associated protein tau-induced endoplasmic reticulum unfolded protein response: implications for Alzheimer's disease. CNS Neurol Disord Drug Targets. 2021;20(5):451-64.
  35. Cho J, Shin M-K, Kim D, Lee I, Kim S, Kang H. Treadmill running reverses cognitive declines due to Alzheimer disease. Med Sci Sports Exerc. 2015;47(9):1814-24.
  36. Peron R, Vatanabe IP, Manzine PR, Camins A, Cominetti MR. Alpha-secretase ADAM10 regulation: insights into Alzheimer’s disease treatment. Pharmaceuticals. 2018;11(1):12.
  37. Page P. Beyond statistical significance: clinical interpretation of rehabilitation research literature. Int J Sports Phys Ther. 2014;9(5):726-36.
  38. Afonso J, Ramirez-Campillo R, Clemente FM, Büttner FC, Andrade R. The perils of misinterpreting and misusing “publication Bias” in meta-analyses: an education review on funnel plot-based methods. Sports Med. 2024;54(2):257-69.
  39. De Felice FG, Munoz DP. Opportunities and challenges in developing relevant animal models for Alzheimer’s disease. Ageing Res Rev. 2016; 26:112-4.
  40. Al Dahhan NZ, De Felice FG, Munoz DP. Potentials and pitfalls of cross-translational models of cognitive impairment. Front Behav Neurosci. 2019; 13:48.
  41. Zhou F-Q, Jiang J, Griffith CM, Patrylo PR, Cai H, Chu Y, et al. Lack of human-like extracellular sortilin neuropathology in transgenic Alzheimer’s disease model mice and macaques. Alzheimer's Res Ther. 2018; 10:1-15.
  42. Azkona G, Sanchez-Pernaute R. Mice in translational neuroscience: What R we doing? Prog Neurobiol. 2022; 217:102330.
  43. Pardo-Moreno T, González-Acedo A, Rivas-Domínguez A, García-Morales V, García-Cozar FJ, Ramos-Rodríguez JJ, et al. Therapeutic approach to Alzheimer’s disease: current treatments and new perspectives. Pharmaceutics. 2022;14(6):1117.
  44. Singh B, Day CM, Abdella S, Garg S. Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management. J Control Release. 2024; 367:402-24.
  45. Ahmad F, Javed M, Athar M, Shahzadi S. Determination of affected brain regions at various stages of Alzheimer's disease. Neurosci Res. 2023; 192:77-82.
  46. Chasseigneaux S, Allinquant B. Functions of Aβ, sAPPα and sAPPβ: similarities and differences. J neurochem. 2012;120(Suppl 1):99-108.
  47. Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The Amyloid-β Pathway in Alzheimer’s Disease. Mol Psychiatry. 2021;26(10):5481-503.
  48. Struble RG, Ala T, Patrylo PR, Brewer GJ, Yan XX. Is brain amyloid production a cause or a result of dementia of the Alzheimer's type? J Alzheimer's Dis. 2010;22(2):393-9.
  49. Haass C, Selkoe D. If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline? PloS Biol. 2022;20(7):e3001694.
  50. Kauwe G, Tracy TE. Amyloid beta emerges from below the neck to disable the brain. PLoS Biol. 2021;19(9): e3001388.
  51. Liu Y, Studzinski C, Beckett T, Murphy MP, Klein RL, Hersh LB. Circulating neprilysin clears brain amyloid. Mol Cel Neurosci. 2010;45(2):101-7.
  52. Marr RA, Guan H, Rockenstein E, Kindy M, Gage FH, Verma I, et al. Neprilysin regulates amyloid β peptide levels. J Mol Neurosci. 2004; 22:5-11.
  53. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron. 2004;43(3):333-44.
  54. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9(7):907-13.
  55. DeMattos RB, Bales KR, Cummins DJ, Dodart J-C, Paul SM, Holtzman DMJPotNAoS. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98(15):8850-5.
  56. Thal DR, Rüb U, Orantes M, Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791-800.
  57. Stephen R, Hongisto K, Solomon A, Lönnroos E. Physical activity and Alzheimer’s disease: a systematic review. J Gerontol A: Biol Sci Med Sci. 2017;72(6):733-9.
  58. Manzine PR, Ettcheto M, Cano A, Busquets O, Marcello E, Pelucchi S, et al. ADAM10 in Alzheimer's disease: pharmacological modulation by natural compounds and its role as a peripheral marker. Biomed Pharmacother. 2019; 113:108661.
  59. Botteri G, Salvadó L, Gumà A, Hamilton DL, Meakin PJ, Montagut G, et al. The BACE1 product sAPPβ induces ER stress and inflammation and impairs insulin signaling. Metabolism. 2018; 85:59-75.
  60. Das B, Singh N, Yao AY, Zhou J, He W, Hu X, et al. BACE1 controls synaptic function through modulating release of synaptic vesicles. Mol Psychiatry. 2021;26(11):6394-410.
  61. Yen S, Wu H-Y, Wang Y, Huang C-M, Wu CW, Chen J-H, et al. Revisiting the effects of exercise on cerebral neurovascular functions in rats using multimodal assessment techniques. iScience. 2023;26(4):354.
  62. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. 2011;108(7):3017-22.
  63. Chao F-l, Zhang L, Zhang Y, Zhou C-n, Jiang L, Xiao Q, et al. Running exercise protects against myelin breakdown in the absence of neurogenesis in the hippocampus of AD mice. Brain Res. 2018; 1684:50-9.
  64. Adlard PA, Perreau VM, Pop V, Cotman CWJJoN. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci. 2005;25(17):4217-21.
  65. Andrade-Guerrero J, Rodríguez-Arellano P, Barron-Leon N, Orta-Salazar E, Ledesma-Alonso C, Díaz-Cintra S, et al. Advancing Alzheimer's therapeutics: exploring the impact of physical exercise in animal models and patients. Cells. 2023;12(21).

  • Receive Date 01 September 2024
  • Revise Date 07 December 2024
  • Accept Date 30 December 2024